

Maria P Garcia-Portilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8925200/publications.pdf>

Version: 2024-02-01

263
papers

6,292
citations

76196

40
h-index

106150

65
g-index

295
all docs

295
docs citations

295
times ranked

7511
citing authors

#	ARTICLE	IF	CITATIONS
1	Emotional intelligence: a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I. <i>Psychological Medicine</i> , 2023, 53, 3065-3076.	2.7	2
2	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2022, 52, 1777-1783.	2.7	10
3	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2022, 52, 1910-1922.	2.7	14
4	Early Impact of the COVID-19 Outbreak on Sleep in a Large Spanish Sample. <i>Behavioral Sleep Medicine</i> , 2022, 20, 100-115.	1.1	15
5	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	0.7	3
6	Sex differences in neurocognitive and psychosocial functioning in bipolar disorder. <i>Journal of Affective Disorders</i> , 2022, 296, 208-215.	2.0	6
7	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110440.	2.5	10
8	Results of the COVID-19 mental health international for the general population (COMET-G) study. <i>European Neuropsychopharmacology</i> , 2022, 54, 21-40.	0.3	84
9	HÁbitos alimenticios y nutricionales en pacientes con esquizofrenia. <i>Revista De PsiquiatrĀa Y Salud Mental</i> , 2022, 15, 54-60.	1.0	5
10	A polygenic approach to the association between smoking and schizophrenia. <i>Addiction Biology</i> , 2022, 27, e13104.	1.4	6
11	Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 620-630.	2.3	18
12	Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-10.	0.9	2
13	Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein levels and metabolic status in patients with a bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 464-474.	1.3	4
14	Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2022, 15, 22-28.	0.2	1
15	Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2022, 15, 14-21.	0.2	2
16	Suicidal Ideation Trends and Associated Factors in Different Large Spanish Samples During the First Year of the COVID-19 Pandemic. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	1.1	3
17	Does COVID-19 psychological fatigue exist? Results of three online cross-sectional studies conducted in Spain from April 2020 to March 2021. <i>Journal of Global Health</i> , 2022, 12, 05001.	1.2	7
18	Is it possible to stage schizophrenia? A systematic review. <i>Translational Psychiatry</i> , 2022, 12, 197.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMiSE trial. <i>European Psychiatry</i> , 2022, 65, .	0.1	4
20	The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.. <i>Psychiatry Research</i> , 2022, 315, 114702.	1.7	17
21	Are older adults also at higher psychological risk from COVID-19?. <i>Aging and Mental Health</i> , 2021, 25, 1297-1304.	1.5	78
22	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	0.7	5
23	Difficulties in delivery and depressive symptomatology in schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 66-68.	0.2	2
24	Consumo de alcohol y factores de riesgo de conductas autolesivas en adolescentes espa�oles. <i>Revista De Psicolog�a De La Salud</i> , 2021, 33, 53.	0.2	4
25	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021, 64, e25.	0.1	18
26	Dificultades en el parto y sintomatolog�a depresiva en la esquizofrenia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, 14, 66-68.	1.0	5
27	Clinical staging in depression. , 2021, , 3-12.		0
28	Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. <i>Comprehensive Psychiatry</i> , 2021, 107, 152233.	1.5	5
29	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8133.	1.2	7
30	Real-World Functioning in Patients With Schizophrenia: Beyond Negative and Cognitive Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 700747.	1.3	8
31	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 236, 19-28.	1.1	5
32	Factors associated with alcohol and tobacco consumption as a coping strategy to deal with the coronavirus disease (COVID-19) pandemic and lockdown in Spain. <i>Addictive Behaviors</i> , 2021, 121, 107003.	1.7	23
33	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. <i>Journal of Affective Disorders</i> , 2021, 295, 173-182.	2.0	32
34	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	4.1	23
35	Spanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, , .	1.0	0
36	Funcionamiento cognitivo en pacientes con trastorno por uso de alcohol que inician tratamiento ambulatorio de deshabituaci�n alcoh�lica. <i>Revista De Psicolog�a De La Salud</i> , 2021, 33, 161.	0.2	2

#	ARTICLE	IF	CITATIONS
37	The mediating role of impulsivity in the relationship between suicidal behaviour and early traumatic experiences in depressed subjects. <i>European Psychiatry</i> , 2021, 64, S583-S583.	0.1	0
38	Orexins in the clinical course of bipolar disorder. <i>European Psychiatry</i> , 2021, 64, S623-S623.	0.1	0
39	Insomnia associated with neutrophil/lymphocyte ratio in female patients with schizophrenia. <i>European Psychiatry</i> , 2021, 64, S806-S806.	0.1	1
40	Association of traumatic events in childhood, impulsivity and decision-making with previous suicide attempt and/or current suicidal ideation in adult patients with major depressive disorder. <i>European Psychiatry</i> , 2021, 64, S177-S178.	0.1	0
41	COVID-19 psychological impact in patients with depressive disorder: Differences based on their age. <i>European Psychiatry</i> , 2021, 64, S674-S675.	0.1	0
42	Factors associated with real-world functioning in first stages of schizophrenia disorder. <i>European Psychiatry</i> , 2021, 64, S805-S805.	0.1	0
43	Spanish Validation of the MAP-SR: Two Heads Better Than One for the Assessment of Negative Symptoms of Schizophrenia. <i>Psicothema</i> , 2021, 33, 473-480.	0.7	0
44	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEL study. <i>Psychological Medicine</i> , 2020, 50, 1884-1897.	2.7	28
45	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	2.3	14
46	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. <i>Schizophrenia Bulletin</i> , 2020, 46, 846-856.	2.3	10
47	Early Psychological Correlates Associated With COVID-19 in A Spanish Older Adult Sample. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 1287-1298.	0.6	30
48	A Smart Band for Automatic Supervision of Restrained Patients in a Hospital Environment. <i>Sensors</i> , 2020, 20, 5211.	2.1	4
49	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. <i>Schizophrenia Research</i> , 2020, 223, 271-278.	1.1	9
50	P.247 Psychological impact of COVID-19 confinement among people with history of mental disorders (bipolar, anxiety, depression) and general population in Spain. <i>European Neuropsychopharmacology</i> , 2020, 40, S141-S142.	0.3	0
51	P.502 Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. <i>European Neuropsychopharmacology</i> , 2020, 40, S281-S282.	0.3	0
52	P.530 Intestinal permeability and low-grade chronic inflammation in schizophrenia: do they influence cognition and cognitive reserve?. <i>European Neuropsychopharmacology</i> , 2020, 40, S297-S298.	0.3	0
53	P.690 Post-traumatic stress symptoms during the COVID-19 in different regions of Spain. <i>European Neuropsychopharmacology</i> , 2020, 40, S393-S394.	0.3	0
54	The Mediating Role of Impulsivity in the Relationship Between Suicidal Behavior and Early Traumatic Experiences in Depressed Subjects. <i>Frontiers in Psychiatry</i> , 2020, 11, 538172.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e182.	1.8	36
56	COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?. <i>Schizophrenia Research</i> , 2020, 223, 192-198.	1.1	64
57	Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene. <i>Schizophrenia Research</i> , 2020, 222, 516-519.	1.1	0
58	Early psychological impact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample. <i>Journal of Global Health</i> , 2020, 10, 020505.	1.2	57
59	Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences. <i>Scientific Reports</i> , 2020, 10, 15963.	1.6	5
60	Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532092634.	1.2	24
61	Sexual Dysfunction and Mood Stabilizers in Long-Term Stable Patients With Bipolar Disorder. <i>Journal of Sexual Medicine</i> , 2020, 17, 930-940.	0.3	8
62	Sex-dependent grades of haematopoietic modulation in patients with major depressive episodes are associated with suicide attempts. <i>European Neuropsychopharmacology</i> , 2020, 40, 17-30.	0.3	10
63	Psychiatry residency during the COVID-19 pandemic: Navigating uncharted waters. <i>Asian Journal of Psychiatry</i> , 2020, 53, 102214.	0.9	2
64	Association of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder. <i>Anxiety, Stress and Coping</i> , 2020, 33, 256-265.	1.7	9
65	Neutrophil-to-lymphocyte ratio: A potential new peripheral biomarker of suicidal behavior. <i>European Psychiatry</i> , 2020, 63, e14.	0.1	51
66	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020, 34, 514-523.	2.0	12
67	Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model. <i>European Neuropsychopharmacology</i> , 2020, 33, 158-163.	0.3	9
68	Sex differences in bipolar disorder: Impact of lifetime cannabis use on clinical course, functioning, and quality of life in bipolar disorder. <i>Journal of Affective Disorders</i> , 2020, 266, 258-262.	2.0	8
69	A clinical staging model for bipolar disorder: longitudinal approach. <i>Translational Psychiatry</i> , 2020, 10, 45.	2.4	14
70	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020, 218, 292-294.	1.1	6
71	¿Se observarán cambios en el consumo de alcohol y tabaco durante el confinamiento por COVID-19?. <i>Revista De Psicología De La Salud</i> , 2020, 32, 85.	0.2	65
72	Prevalence of Passive Suicidal Ideation in the Early Stage of the Coronavirus Disease 2019 (COVID-19) Pandemic and Lockdown in a Large Spanish Sample. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	16

#	ARTICLE	IF	CITATIONS
73	Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2020, , .	1.0	2
74	Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2020, , .	1.0	2
75	Antipsic�ticos inyectables de liberaci�n prolongada para el tratamiento de la esquizofrenia en Espa�a. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2019, 12, 92-105.	1.0	23
76	Phenotypic factors associated with amisulpride�induced weight gain in first�episode psychosis patients (from the OPT iMi SE cohort). <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 283-290.	2.2	6
77	Clinical staging in severe mental disorders: Bipolar disorder, depression and schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2019, 12, 106-115.	0.2	7
78	�Readiness to Change� Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. <i>European Addiction Research</i> , 2019, 25, 256-262.	1.3	3
79	Prepare the smoking cessation in severe mental illness: Early diagnosis and prevention opportunities. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2019, 12, 133-134.	0.2	0
80	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 960-965.	2.3	46
81	Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology. <i>Psychiatry Research</i> , 2019, 280, 112509.	1.7	19
82	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. <i>Frontiers in Psychiatry</i> , 2019, 10, 676.	1.3	5
83	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	1.0	28
84	Classification of patients with bipolar disorder using k-means clustering. <i>PLoS ONE</i> , 2019, 14, e0210314.	1.1	36
85	Are altered plasma vitamin D, vitamin A and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?. <i>European Neuropsychopharmacology</i> , 2019, 29, S431-S432.	0.3	0
86	Association of childhood trauma and genetic variability of CRH-BP and FKBP5 genes with suicidal behavior in bipolar patients. <i>Journal of Affective Disorders</i> , 2019, 255, 15-22.	2.0	20
87	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. <i>World Psychiatry</i> , 2019, 18, 173-182.	4.8	127
88	Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use. <i>European Neuropsychopharmacology</i> , 2019, 29, S238-S239.	0.3	1
89	Can interleukin-2 and interleukin-1� be specific biomarkers of negative symptoms in schizophrenia?. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2019, 12, 9-16.	0.2	0
90	History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders. <i>European Addiction Research</i> , 2019, 25, 111-118.	1.3	7

#	ARTICLE	IF	CITATIONS
91	F110. SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING. Schizophrenia Bulletin, 2019, 45, S295-S296.	2.3	0
92	Breadth and depth of working memory and executive function compromises in mild cognitive impairment and their relationships to frontal lobe morphometry and functional competence. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 170-179.	1.2	24
93	Emotion recognition in major depressed patients: Evidence of lack of relationship with suicidal behavior. European Neuropsychopharmacology, 2019, 29, S376-S377.	0.3	0
94	Los cambios estructurales de la retina, ¿nuevos biomarcadores de los trastornos mentales? Una revisión sistemática y síntesis temática de la literatura. Revista De Psiquiatría Y Salud Mental, 2019, 12, 116-129.	1.0	9
95	Spanish validation of the Barcelona TEMPS-A questionnaire in patients with bipolar disorder and general population. Journal of Affective Disorders, 2019, 249, 199-207.	2.0	11
96	Neuroticism modulates HPA axis reactivity during the first trimester of pregnancy. Psychoneuroendocrinology, 2019, 107, 27.	1.3	0
97	P.378 Metabolic syndrome and quality of life in schizophrenia and bipolar disorder. European Neuropsychopharmacology, 2019, 29, S268-S269.	0.3	0
98	P.586 Comorbid depression in patients with schizophrenia: does it have an impact on their neurocognitive functioning?. European Neuropsychopharmacology, 2019, 29, S407-S408.	0.3	0
99	Estadificación clínica en los trastornos mentales graves: trastorno bipolar, depresión y esquizofrenia. Revista De Psiquiatría Y Salud Mental, 2019, 12, 106-115.	1.0	15
100	Smoking Status and Cost of Illness in Patients with Depressive Disorder Based on the National Health Survey in Spain. Substance Use and Misuse, 2019, 54, 713-723.	0.7	2
101	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 2019, 56, 14-34.	0.1	330
102	Are plasma 25-hydroxyvitamin D and retinol levels and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?. Psychiatry Research, 2019, 273, 22-29.	1.7	2
103	¿Es la alteración en el reconocimiento emocional un factor de riesgo específico de tentativa suicida?. Revista De Psiquiatría Y Salud Mental, 2019, 12, 196-198.	1.0	3
104	Preparar la cesación tabáquica en el trastorno mental grave: diagnóstico precoz y oportunidades de prevención. Revista De Psiquiatría Y Salud Mental, 2019, 12, 133-134.	1.0	2
105	Influence of secondary sources in the Brief Negative Symptom Scale. Schizophrenia Research, 2019, 204, 452-454.	1.1	5
106	Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE). Psychological Medicine, 2019, 49, 2600-2607.	2.7	10
107	Early versus late stage schizophrenia. What markers make the difference?. World Journal of Biological Psychiatry, 2019, 20, 159-165.	1.3	3
108	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychological Medicine, 2019, 49, 1378-1391.	2.7	69

#	ARTICLE	IF	CITATIONS
109	<i>5-HTTLPR</i> brain-derived neurotrophic factor (<i>BDNF</i>) gene interactions and early adverse life events effect on impulsivity in suicide attempters. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 137-149.	1.3	17
110	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 305-314.	2.3	99
111	¿Pueden ser la interleucina-2 y la interleucina-1 ² biomarcadores específicos de la sintomatología negativa en la esquizofrenia?. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 9-16.	1.0	8
112	Factores asociados con consumo de tabaco en pacientes con depresión. <i>Revista De Psicología De La Salud</i> , 2019, 31, 298.	0.2	12
113	Prevention of recurrent suicidal behavior: Case management and psychoeducation. <i>Psicothema</i> , 2019, 31, 107-113.	0.7	5
114	Factores predictores del consumo de alcohol en adolescentes: datos de un estudio prospectivo de 1 año de seguimiento. <i>Revista De Psicología De La Salud</i> , 2019, 31, 52-63.	0.2	2
115	Consumo de cannabis y alteraciones cognitivas en esquizofrenia y primeros episodios psicóticos. <i>Revista De Psicología De La Salud</i> , 2019, 31, 89.	0.2	2
116	Tratamiento farmacológico del trastorno obsesivo-compulsivo en adultos: una guía de práctica clínica basada en el método ADAPTE. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 77-91.	1.0	5
117	Validación española de la escala de evaluación de los síntomas negativos-16 (NSA-16) en pacientes con esquizofrenia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2018, 11, 169-175.	1.0	5
118	Smoking does not impact social and non-social cognition in patients with first episode psychosis. <i>Schizophrenia Research</i> , 2018, 199, 64-74.	1.1	13
119	Association between genetic variation in the myo-inositol monophosphatase 2 (IMPA2) gene and age at onset of bipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 232, 229-236.	2.0	8
120	Are affective temperaments determinants of quality of life in euthymic patients with bipolar disorder?. <i>Journal of Affective Disorders</i> , 2018, 230, 101-107.	2.0	5
121	Gender differences in C-reactive protein and homocysteine modulation of cognitive performance and real-world functioning in bipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 229, 95-104.	2.0	24
122	Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 145-154.	2.2	60
123	Biomarcadores de estrés oxidativo y dimensiones clínicas en los 10 primeros años de esquizofrenia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2018, 11, 130-140.	1.0	15
124	Inverse association between negative symptoms and body mass index in chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 69-74.	1.1	25
125	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 188-196.	1.1	50
126	Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls. <i>European Psychiatry</i> , 2018, 47, 50-59.	0.1	32

#	ARTICLE	IF	CITATIONS
127	Deep Brain Stimulation in Patients with Parkinson's Disease: Effect on Psychiatric Symptoms and Quality of Life. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2018, 79, 130-138.	0.4	2
128	S240. DETERMINANT FACTORS OF REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S420-S420.	2.3	0
129	T17. OXIDATIVE STRESS BIOMARKERS AND NEGATIVE DIMENSION IN THE FIRST TEN YEARS OF SCHIZOPHRENIA: A 1-YEAR FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S119-S119.	2.3	0
130	Obstetric Phenotypes in the Heterogeneity of Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 882-886.	0.5	18
131	Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia. <i>Psychiatry Research</i> , 2018, 269, 688-691.	1.7	7
132	Sleep disturbances, functioning, and quality of life in euthymic patients with bipolar disorder. <i>Psychiatry Research</i> , 2018, 269, 501-507.	1.7	23
133	Characterizing decision-making and reward processing in bipolar disorder: A cluster analysis. <i>European Neuropsychopharmacology</i> , 2018, 28, 863-874.	0.3	16
134	Genome wide analysis of rare copy number variations in alcohol abuse or dependence. <i>Journal of Psychiatric Research</i> , 2018, 103, 212-218.	1.5	8
135	Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2018, 11, 130-140.	0.2	7
136	Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2018, 11, 169-175.	0.2	0
137	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTIMISE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	3.7	141
138	Functional recovery in patients with schizophrenia: recommendations from a panel of experts. <i>BMC Psychiatry</i> , 2018, 18, 176.	1.1	38
139	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
140	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. <i>European Neuropsychopharmacology</i> , 2017, 27, 350-359.	0.3	26
141	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , 2017, 189, 84-90.	1.1	49
142	Suicidio, desempleo y recesi�n econ�mica en Espa�a. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2017, 10, 70-77.	1.0	33
143	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
144	EPICOG-SCH: A brief battery to screen cognitive impact of schizophrenia in stable outpatients. <i>Schizophrenia Research: Cognition</i> , 2017, 8, 7-20.	0.7	2

#	ARTICLE	IF	CITATIONS
145	Impact of childhood trauma on cognitive profile in bipolar disorder. <i>Bipolar Disorders</i> , 2017, 19, 363-374.	1.1	49
146	Physical Health in Early and Late Stages of Bipolar Disorder. <i>European Psychiatry</i> , 2017, 41, s113-s113.	0.1	0
147	Recomendaciones preventivas sobre el uso de Ácido valproico en mujeres embarazadas o con capacidad de gestaci3n para tener muy presentes. <i>Revista De PsiquiatrĀa Y Salud Mental</i> , 2017, 10, 129-133.	1.0	5
148	Preventive recommendations on the use of valproic acid in pregnant or gestational women to be very present. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2017, 10, 129-133.	0.2	0
149	Usefulness of the Short Personality and Life Event Scale (S-PLE) for detection of suicide attempters. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2017, 10, 218-219.	0.2	1
150	A prop3sito de la utilidad de la Escala Abreviada de Personalidad y Acontecimientos Vitales (S-PLE) en la detecci3n de las tentativas de suicidio. <i>Revista De PsiquiatrĀa Y Salud Mental</i> , 2017, 10, 218-219.	1.0	7
151	Tabaco y rendimiento cognitivo en pacientes con esquizofrenia: dise±o del estudio COGNICO. <i>Revista De Psicología De La Salud</i> , 2017, 29, 6.	0.2	4
152	Uso y abuso de sustancias psicotr3picas e internet, psicopatologĀa e ideaci3n suicida en adolescentes. <i>Revista De Psicología De La Salud</i> , 2017, 29, 97.	0.2	51
153	Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 266-276.	2.2	35
154	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2016, 9, 219-227.	0.2	6
155	Smoking cessation programs for persons with schizophrenia: An urgent unmet need. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2016, 9, 181-184.	0.2	3
156	Programas de cesaci3n tabĀiquica para personas con esquizofrenia: una necesidad urgente no cubierta. <i>Revista De PsiquiatrĀa Y Salud Mental</i> , 2016, 9, 181-184.	1.0	13
157	Inflammatory and metabolic biomarkers of psychopathological dimensions of schizophrenia. <i>European Psychiatry</i> , 2016, 33, s250-s250.	0.1	1
158	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. <i>Psychological Medicine</i> , 2016, 46, 291-301.	2.7	43
159	Differential serum acute-phase biomarker profile in schizophrenia and bipolar disorder. <i>European Psychiatry</i> , 2016, 33, S96-S96.	0.1	1
160	Biomarcadores sanguĀneos diferenciales de las dimensiones psicopatol3gicas de la esquizofrenia. <i>Revista De PsiquiatrĀa Y Salud Mental</i> , 2016, 9, 219-227.	1.0	21
161	Validation of a Spanish version of the Columbia-Suicide Severity Rating Scale (C-SSRS). <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2016, 9, 134-142.	0.2	19
162	MĀtodos de exploraci3n de la funci3n cognitiva en la prĀctica clĀnica. <i>Psiquiatria Biologica</i> , 2016, 23, 29-33.	0.0	14

#	ARTICLE	IF	CITATIONS
163	Evolution of negative symptom assessment instruments. <i>European Psychiatry</i> , 2016, 33, S69-S69.	0.1	0
164	Childhood trauma in suicide attempters: Case-control study. <i>European Psychiatry</i> , 2016, 33, S111-S111.	0.1	2
165	Effects of nicotine abstinence on clinical symptoms. Study at 3 and 6-months follow-up of outpatients with schizophrenia. <i>European Psychiatry</i> , 2016, 33, s261-s262.	0.1	1
166	Psychometric properties of a Spanish-version of the Schizophrenia Objective Functioning Instrument (Sp-SOFI). <i>International Journal of Clinical and Health Psychology</i> , 2016, 16, 58-75.	2.7	5
167	Validación de la versión en español de la Columbia-Suicide Severity Rating Scale (Escala Columbia para) Tj ETQq1_1 0.784314 rgBT	1.0	50
168	It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline. <i>Schizophrenia Research</i> , 2016, 176, 272-280.	1.1	22
169	Reasons for Attempted Suicide in Europe: Prevalence, Associated Factors, and Risk of Repetition. <i>Archives of Suicide Research</i> , 2016, 20, 45-58.	1.2	38
170	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. <i>British Journal of Psychiatry</i> , 2016, 208, 87-93.	1.7	95
171	Diferencias de género en la gravedad de la adicción. <i>Revista De Psicología De La Salud</i> , 2016, 28, 221.	0.2	14
172	Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 600-604.	0.7	20
173	Cognitive Performance associated to functional outcomes in stable outpatients with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 146-158.	0.7	19
174	Predictors of Posttreatment Drinking Outcomes in Patients with Alcohol Dependence. <i>European Addiction Research</i> , 2015, 21, 19-30.	1.3	11
175	Predictive factors of functional capacity and real-world functioning in patients with schizophrenia. <i>European Psychiatry</i> , 2015, 30, 622-627.	0.1	40
176	Psychometric evaluation of the negative syndrome of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 559-566.	1.8	50
177	The negative syndrome of schizophrenia: Three underlying components are better than two. <i>Schizophrenia Research</i> , 2015, 166, 115-118.	1.1	18
178	Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms. <i>European Neuropsychopharmacology</i> , 2015, 25, 257-264.	0.3	52
179	Factors Associated with Hospitalization after Suicide Spectrum Behaviors: Results from a Multicenter Study in Spain. <i>Archives of Suicide Research</i> , 2015, 19, 17-34.	1.2	15
180	Effectiveness of a Multi-Component Smoking Cessation Support Programme (McSCSP) for Patients with Severe Mental Disorders: Study Design. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 373-389.	1.2	6

#	ARTICLE	IF	CITATIONS
181	Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 376-387.	2.3	156
182	Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 272-284.	1.1	36
183	Study protocol of a prevention of recurrent suicidal behaviour program based on case management (PSyMAC). <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2014, 7, 131-138.	0.2	3
184	P.2.d.039 Functional remediation in bipolar II patients: improvement of functioning and subsyndromal symptoms. <i>European Neuropsychopharmacology</i> , 2014, 24, S436-S437.	0.3	4
185	Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2014, 7, 113-120.	0.2	2
186	P.6.d.014 Psychopathological tolerability of varenicline and nicotine patches for smoking cessation in severe mental disorders. <i>European Neuropsychopharmacology</i> , 2014, 24, S694.	0.3	0
187	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. <i>Schizophrenia Research</i> , 2014, 159, 107-113.	1.1	36
188	Spanish adaptation and validation of the Brief Negative Symptoms Scale. <i>Comprehensive Psychiatry</i> , 2014, 55, 1726-1729.	1.5	54
189	Association between GSK3 β gene and increased impulsivity in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2014, 24, 510-518.	0.3	25
190	Patolog�a dual en trastornos de ansiedad: recomendaciones en el tratamiento farmacol�gico. <i>Revista De Psicolog�a De La Salud</i> , 2014, 26, 254.	0.2	8
191	Guilt and depression: Two different factors in individuals with negative symptoms of schizophrenia. <i>European Psychiatry</i> , 2013, 28, 327-331.	0.1	19
192	Genetic variability at IMPA2, INPP1 and GSK3 β increases the risk of suicidal behavior in bipolar patients. <i>European Neuropsychopharmacology</i> , 2013, 23, 1452-1462.	0.3	46
193	Ante el nuevo reto de identificar el s�ndrome negativo de la esquizofrenia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2013, 6, 141-143.	1.0	17
194	Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2013, 150, 421-426.	1.1	31
195	P.7.e.003 Sleep in adolescents: association with emotional problems and suicidal ideation. <i>European Neuropsychopharmacology</i> , 2013, 23, S613-S614.	0.3	0
196	P.2.d.014 Genetic variability at IMPA2 and INPP1 genes is associated to lithium response in bipolar patients. <i>European Neuropsychopharmacology</i> , 2013, 23, S370-S371.	0.3	1
197	Evoluci�n de la prevalencia administrativa de los trastornos mentales durante 13 a�os en Asturias (norte de Espa�a). <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2013, 6, 60-66.	1.0	8
198	Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. <i>American Journal of Psychiatry</i> , 2013, 170, 852-859.	4.0	269

#	ARTICLE	IF	CITATIONS
199	The state of psychiatry in Spain. <i>International Review of Psychiatry</i> , 2012, 24, 347-355.	1.4	5
200	Development of the insight scale for affective disorders (ISAD): Modification from the scale to assess unawareness of mental disorder. <i>Journal of Affective Disorders</i> , 2012, 142, 65-71.	2.0	30
201	Depressive disorders and the menopause transition. <i>Maturitas</i> , 2012, 71, 120-130.	1.0	172
202	Psychometric properties of the Spanish version of the Body Weight, Image and Self-Esteem Evaluation questionnaire in patients with severe mental disorders. <i>Comprehensive Psychiatry</i> , 2012, 53, 1237-1242.	1.5	3
203	New treatment guidelines for acute bipolar mania: A critical review. <i>Journal of Affective Disorders</i> , 2012, 140, 125-141.	2.0	76
204	The Incidence of Hospital-Treated Attempted Suicide in Oviedo, Spain. <i>Crisis</i> , 2012, 33, 46-53.	0.9	20
205	A 25-year follow-up of patients admitted to methadone treatment for the first time: Mortality and gender differences. <i>Addictive Behaviors</i> , 2011, 36, 1184-1190.	1.7	51
206	Role of serotonergic-related systems in suicidal behavior: Data from a case-control association study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1518-1524.	2.5	21
207	A cross-cultural comparison between Spain and the USA: Temperament and character distribution by sex and age. <i>Psychiatry Research</i> , 2011, 186, 397-401.	1.7	12
208	Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2011, 4, 9-18.	0.2	21
209	Self-Perceived Needs Are Related to Violent Behavior Among Schizophrenia Outpatients. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 666-671.	0.5	10
210	Psychometric Properties of the Spanish Version of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) in Patients with Severe Mental Disorders. <i>Journal of Sexual Medicine</i> , 2011, 8, 1371-1382.	0.3	24
211	Sexual Function Assessment in Postmenopausal Women with the 14-item Changes in Sexual Functioning Questionnaire. <i>Journal of Sexual Medicine</i> , 2011, 8, 2144-2151.	0.3	41
212	Validación de la versión española de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable. <i>Revista De Psiquiatría Y Salud Mental</i> , 2011, 4, 9-18.	1.0	65
213	Borderline Personality Traits in Nonclinical Young Adults. <i>Journal of Personality Disorders</i> , 2011, 25, 542-556.	0.8	29
214	Topiramate for the Treatment of Alcohol Dependence: Comparison with Naltrexone. <i>European Addiction Research</i> , 2011, 17, 29-36.	1.3	49
215	Amisulpride en el tratamiento de la dependencia alcohólica. <i>Revista De Psicología De La Salud</i> , 2011, 23, 149.	0.2	2
216	Impact of substance use on the physical health of patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2010, 121, 437-445.	2.2	31

#	ARTICLE	IF	CITATIONS
217	Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians. <i>Psychiatric Genetics</i> , 2010, 20, 171-178.	0.6	19
218	Sociodemographic factors associated with personality traits assessed through the TCI. <i>Personality and Individual Differences</i> , 2010, 48, 809-814.	1.6	9
219	Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1494-1497.	1.1	34
220	Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 26-31.	2.5	37
221	P.1.h.003 Prevalence of metabolic syndrome and cardiovascular risk in patients with schizoaffective disorders. <i>European Neuropsychopharmacology</i> , 2010, 20, S323-S324.	0.3	0
222	Measurement Invariance of the Reynolds Depression Adolescent Scale across Gender and Age. <i>International Journal of Testing</i> , 2010, 10, 133-148.	0.2	21
223	Cardiovascular risk in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2009, 115, 302-308.	2.0	68
224	Polymorphisms of the IL6 Gene Complex Are Associated With Alcohol Dependence in Spanish Caucasians: Data From an Association Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 2147-2153.	1.4	19
225	Differential role of serotonergic polymorphisms in alcohol and heroin dependence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 695-700.	2.5	35
226	Differences Observed by ASI-6 among users of Alcohol, Cocaine and Opiates. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
227	Physical Health of Patients with Drug use Disorders. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
228	Substance Use and Physical Health in Patients with Bipolar Disorder Under Maintenance Treatment. <i>European Psychiatry</i> , 2009, 24, .	0.1	1
229	Implicación de polimorfismos serotoninérgicos en la gravedad clínica del trastorno de pánico. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009, 2, 35-41.	1.0	5
230	Rendimiento psicométrico del Cuestionario Oviedo de Sueño en pacientes con trastorno mental grave. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009, 2, 169-177.	1.0	21
231	Role of serotonergic polymorphisms in the clinical severity of the panic disorder. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2009, 2, 35-41.	0.2	1
232	Using Topiramate or Naltrexone for the Treatment of Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1251-1259.	1.4	64
233	The prevalence of metabolic syndrome in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2008, 106, 197-201.	2.0	107
234	Is attempted suicide different in adolescent and adults?. <i>Psychiatry Research</i> , 2008, 157, 131-137.	1.7	49

#	ARTICLE	IF	CITATIONS
235	Association study between obsessive-compulsive disorder and serotonergic candidate genes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 765-770.	2.5	47
236	Association between Heroin Dependence and 5-HT _{2A} Receptor Gene Polymorphisms. <i>European Addiction Research</i> , 2008, 14, 47-52.	1.3	20
237	Association Between the Stin2 VNTR Polymorphism of the Serotonin Transporter Gene and Treatment Outcome in Alcohol-Dependent Patients. <i>Alcohol and Alcoholism</i> , 2008, 43, 516-522.	0.9	26
238	Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts. <i>Psychiatric Genetics</i> , 2008, 18, 147-150.	0.6	11
239	Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. <i>Psychiatric Genetics</i> , 2008, 18, 213-218.	0.6	29
240	Cannabis and mental health. <i>Journal of Psychiatric Intensive Care</i> , 2007, 3, .	0.2	2
241	Association study of serotonin 2A receptor (5-HT _{2A}) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 741-745.	2.5	38
242	The prevalence of the metabolic syndrome in bipolar patients. <i>European Psychiatry</i> , 2007, 22, S252.	0.1	2
243	P.3.c.037 Neuropsychological performance and cognitive disability in schizophrenia outpatients. <i>European Neuropsychopharmacology</i> , 2007, 17, S445-S446.	0.3	0
244	Lack of association between endothelial nitric oxide synthase (NOS3) gene polymorphisms and suicide attempts. <i>Behavioral and Brain Functions</i> , 2007, 3, 32.	1.4	6
245	Quality of life in schizophrenic patients. <i>Dialogues in Clinical Neuroscience</i> , 2007, 9, 215-226.	1.8	128
246	Negative evidences in association between apolipoprotein E polymorphism and panic disorder. <i>European Psychiatry</i> , 2006, 21, 59-61.	0.1	5
247	N-acetyltransferase-2 polymorphisms and schizophrenia. <i>European Psychiatry</i> , 2006, 21, 333-337.	0.1	5
248	Interleukin-1 Gene Complex in Schizophrenia: An Association Study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 678-680.	1.1	12
249	Quality of life measures in schizophrenia. <i>European Psychiatry</i> , 2005, 20, S313-S317.	0.1	79
250	Serotonin gene polymorphisms in patients with panic disorder. <i>Actas Espanolas De Psiquiatria</i> , 2005, 33, 210-5.	0.1	21
251	Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. <i>Schizophrenia Research</i> , 2003, 62, 77-88.	1.1	113
252	Frequency of Sexual Dysfunction and Other Reproductive Side-effects in Patients with Schizophrenia Treated with Risperidone, Olanzapine, Quetiapine, or Haloperidol: The Results of the EIRE Study. <i>Journal of Sex and Marital Therapy</i> , 2003, 29, 125-147.	1.0	178

#	ARTICLE	IF	CITATIONS
253	Evaluating Changes in Sexual Functioning in Depressed Patients: Sensitivity to Change of the CSFQ. <i>Journal of Sex and Marital Therapy</i> , 2002, 28, 93-103.	1.0	24
254	Use of MDMA and Other Illicit Drugs by Young Adult Males in Northern Spain. <i>European Addiction Research</i> , 2002, 8, 147-154.	1.3	29
255	Is antipsychotic-induced weight gain related to sexual dysfunction?. <i>European Neuropsychopharmacology</i> , 2002, 12, 282-283.	0.3	0
256	Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol. <i>Clinical Drug Investigation</i> , 2002, 22, 609-622.	1.1	9
257	High Degree of Tolerability for Monotherapy With High Doses of Quetiapine. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 1048-1049.	1.1	11
258	Quality of life and disability in patients with obsessive-compulsive disorder. <i>European Psychiatry</i> , 2001, 16, 239-245.	0.1	201
259	Validation of the Spanish Version of the Changes in Sexual Functioning Questionnaire (CSFQ). <i>Journal of Sex and Marital Therapy</i> , 2000, 26, 119-131.	1.0	33
260	Sexual dysfunction in depressed patients undergoing treatment with antidepressants. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 311-317.	1.2	7
261	Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. <i>European Psychiatry</i> , 1998, 13, 158-163.	0.1	30
262	Searching for a predictive peripheral biological model in parasuicidal behaviour. <i>European Psychiatry</i> , 1997, 12, 75-81.	0.1	7
263	Symptoms of Depression in Alzheimer's Disease, Frontal Lobe-type Dementia, and Subcortical Dementia. <i>Annals of the New York Academy of Sciences</i> , 1995, 769, 389-392.	1.8	15